Compare Super Micro Computer Inc (SMCI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Super Micro Computer Inc trades at $35.09 (market cap $25.67B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Super Micro Computer Inc is far larger — about 3.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 20 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SMCI | SYRE | |
|---|---|---|
Market Cap | $25.67B | $7.52B |
Volume | 24,555,322 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $55.04 | $108.92 |
52-Week Low | $20.53 | $22.18 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $31.13B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $39.07, down 2.28% today, with a bullish technical signal and strong fundamental growth. The stock shows robust earnings beats, with Q2 2026 EPS of $1.70 exceeding the $0.923 estimate, and revenue is projected to grow from $22.0B in 2025 to $39.1B in 2026. Analyst consensus is a $42.33 price target, with 36% buy ratings. Recent news highlights AI-driven order surges and new NVIDIA Vera Rubin shipments, supporting positive sentiment amid competitive pressures.
The outlook for SMCI is positive, driven by AI infrastructure demand and earnings momentum, but risks include margin pressure and a Department of Justice investigation. Valuation remains attractive with a P/E of 11.98, though debt levels and market volatility warrant caution. Upside potential exists if the company maintains its growth trajectory and navigates legal challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
